NCT06483997 is a clinical trial in Breast Cancer Female, sponsored by George Washington University.

Who is sponsoring NCT06483997?

NCT06483997 is sponsored by George Washington University.

What condition does NCT06483997 study?

NCT06483997 studies Breast Cancer Female, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Endometrial Cancer, Gynecologic Cancer.

Is NCT06483997 still recruiting?

NCT06483997 is currently active, enrolled. Last updated 27 January 2026.

Last reviewed 2026-01-27 · How we verify

NCT06483997

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Associations Between Diet, Hepcidin, and Relative Dose Intensity Among Women Receiving Chemotherapy for Breast or Gynecological Cancer

Active, enrolled Last updated 27 January 2026

What this trial tests

trial in Breast Cancer Female in 100 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

16 August 2024

Primary endpoint
1 July 2026

1 July 2026

Quick facts

Lead sponsor	George Washington University
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	100
Start date	16 August 2024
Primary completion	1 July 2026
Estimated completion	1 July 2026
Sites	1 location across United States

Conditions studied

Breast Cancer Female — all drugs for Breast Cancer Female →
Ovarian Cancer — all drugs for Ovarian Cancer →
Fallopian Tube Cancer — all drugs for Fallopian Tube Cancer →
Primary Peritoneal Carcinoma — all drugs for Primary Peritoneal Carcinoma →

Sponsor

George Washington University

Who can join

21 and older, female only, with Breast Cancer Female or Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Serum hepcidin concentration
Time frame: pre-chemotherapy, single measure
ng/ml, continuous
Chemotherapy relative dose intensity
Time frame: during chemotherapy (up to 6 months, depends on duration of chemotherapy regimen), represents repeated measures
Calculated variable that represents the ratio of chemotherapy actually received during the duration of treatment to the planned chemotherapy dose during the planned duration

Sponsor's own description

This prospective, observational cohort study will evaluate the extent of associations between self-reported pro- or anti- inflammatory dietary intake patterns for one month before induction chemotherapy for gynecological cancer or neo/adjuvant chemotherapy for breast cancer and baseline serum hepcidin concentrations. Associations between hepcidin concentration and relative dose intensity (RDI) of chemotherapy will also be evaluated.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Antimicrobial peptides: from discovery to developmental applications.
Zhang Q. · · 2025 · cited 20× · PMID 40178173 · DOI 10.1128/aem.02115-24

Verify or expand the search:

Other recruiting trials for Breast Cancer Female

Currently open trials in the same condition.

NCT07505797 — ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) · recruiting
NCT07198724 — ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrin · Phase 1, PHASE2 · recruiting
NCT07331506 — Validation of the Oncoliq Test for the Early Detection of Breast Cancer. · recruiting
NCT07214883 — UCF MammoChat: Image Repository · recruiting
NCT07120100 — Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Surviv · NA · recruiting

Other George Washington University trials

Trials by the same sponsor.

NCT07279129 — Decision Support Tool to Integrate PrEP Into Emergency Departments · Phase 1 · not yet recruiting
NCT07524309 — Self-Help Plus Pilot Study, Colombia: Train2Care · NA · not yet recruiting
NCT07249008 — NSS Grocery Store Brazil · NA · recruiting
NCT07000513 — HIV Self-Testing and Long-Acting Injectables for HIV Treatment and Prevention Among Commercial Minibus Drivers (I-TEST L · Phase 4 · not yet recruiting
NCT07079306 — ChatGPT-Supported Text Messaging Program for Smoking Cessation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06483997 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by George Washington University
Last refreshed: 27 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06483997.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing